Stock Research for ADRD

Current Price


Latest Update: 2018-03-16 11:22:00

$ 23.2510
$ 23.2510
$ 23.2510

Featured Broker: TradeStation

Get the due diligence for another stock.


ADRD Stock Chart & Research Data

The ADRD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADRD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ADRD Due diligence Resources & Stock Charts

The ADRD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADRD Detailed Price Forecast - CNN Money CNN View ADRD Detailed Summary - Google Finance
Yahoo View ADRD Detailed Summary - Yahoo! Finance Zacks View ADRD Stock Research & Analysis -

Stock Analysis

TradeIdeas View ADRD Trends & Analysis - Trade-Ideas Barrons View ADRD Major Holders - Barrons
NASDAQ View ADRD Call Transcripts - NASDAQ Seeking View ADRD Breaking News & Analysis - Seeking Alpha
Spotlight View ADRD Annual Report - OTC Report View ADRD OTC Short Report -
TradeKing View ADRD Fundamentals - TradeKing Charts View ADRD SEC Filings - Bar Chart
WSJ View Historical Prices for ADRD - The WSJ Morningstar View Performance/Total Return for ADRD - Morningstar
MarketWatch View the Analyst Estimates for ADRD - MarketWatch CNBC View the Earnings History for ADRD - CNBC
StockMarketWatch View the ADRD Earnings - StockMarketWatch MacroAxis View ADRD Buy or Sell Recommendations - MacroAxis
Bullish View the ADRD Bullish Patterns - American Bulls Short Pains View ADRD Short Pain Metrics -

Social Media Mentions

StockTwits View ADRD Stock Mentions - StockTwits PennyStocks View ADRD Stock Mentions - PennyStockTweets
Twitter View ADRD Stock Mentions - Twitter Invest Hub View ADRD Investment Forum News - Investor Hub
Yahoo View ADRD Stock Mentions - Yahoo! Message Board Seeking Alpha View ADRD Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ADRD - Insider Cow View Insider Transactions for ADRD - Insider Cow
CNBC View ADRD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADRD - OTC Markets
Yahoo View Insider Transactions for ADRD - Yahoo! Finance NASDAQ View Institutional Holdings for ADRD - NASDAQ

Stock Charts

FinViz View ADRD Stock Insight & Charts - StockCharts View ADRD Investment Charts -
BarChart View ADRD Stock Overview & Charts - BarChart Trading View View ADRD User Generated Charts - Trading View

Latest Financial News for ADRD

What Analysts Recommend for AstraZeneca in March 2018
Posted on Wednesday March 14, 2018

As discussed earlier, AstraZeneca surpassed Wall Street analyst estimates for earnings per share (or EPS) and revenues and reported EPS of $1.03 on revenues of ~$5.8 billion in 4Q17, a 3% increase in revenues as compared to revenues of 4Q16. AstraZeneca’s stock price has increased by nearly 14.9% over the last 12 months but decreased by ~2.6% in 2018 year-to-date. Wall Street analysts have a 12-month target price of $39.09 per share as compared to the last price of $33.78 per share as of March 8, 2018.

Sanofi’s Established Prescription Products in 4Q17
Posted on Friday March 02, 2018

Must-Read Notes on Sanofi's 4Q17 Earnings

Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform
Posted on Friday February 09, 2018

Ablynx (ABLX) is a Belgium-based biopharmaceutical company engaged in the development and commercialization of nanobodies. Ablynx currently has more than 45 proprietary and partnered programs for the development of new treatments in the therapeutic areas of hematology, inflammation, respiratory disease, oncology, and immuno-oncology. The company has existing collaborations with a number of pharma giants, including Novartis (NVS), Merck & Co. (MRK), and AbbVie (ABBV). Ablynx is listed on Euronext Brussels and the NASDAQ.

Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights
Posted on Wednesday February 07, 2018

On January 22, 2018, Sanofi (SNY) announced that it had entered into an agreement with Bioverativ (BIVV) to acquire all of its outstanding shares for $105 per share in cash. The acquisition price of $105 per share represented a premium of 64% to Bioverativ stock’s closing price on January 19, 2018. The boards of directors of Sanofi and Bioverativ unanimously approved the acquisition.

Warning: DOMDocument::load( failed to open stream: HTTP request failed! HTTP/1.0 404 Not Found in /home/allsites/ on line 494

Warning: DOMDocument::load(): I/O warning : failed to load external entity "" in /home/allsites/ on line 494

Enter a stock symbol to view the stock details.